GlassScriptPhysician profile
Richard W Young
NPI 1518948587
$10,623.65
in general payments reported to CMS, 2019-2025
59 companies · $773 in 2025
The $773 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,619 · 2020: $418 · 2021: $2,322 · 2022: $2,133 · 2023: $1,245 · 2024: $2,114 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,131.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,833.42 | 2022-2025 | Urolift, Barrigel |
| Neotract INC. | $1,322.76 | 2019 | |
| Cipla USA INC. | $906.90 | 2021 | |
| Dendreon Pharmaceuticals LLC | $859.51 | 2019-2025 | Provenge |
| Boston Scientific Corporation | $603.05 | 2019-2025 | Rezum Generator, Axonics |
| Antares Pharma, INC. | $444.74 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Coloplast Corp | $310.34 | 2019-2024 | Speedicath |
| Procept Biorobotics Corporation | $254.01 | 2023-2025 | Aquabeam Robotic System |
| Blue Earth Diagnostics | $250.19 | 2019-2024 | |
| Myriad Genetic Laboratories, INC. | $242.89 | 2021-2024 | Prolaris |
| Urogen Pharma, INC. | $231.48 | 2020-2025 | |
| Abbvie INC. | $221.69 | 2022-2025 | Botox |
| Sumitomo Pharma America, INC. | $213.95 | 2023-2025 | Gemtesa |
| Pfizer INC. | $206.49 | 2020-2025 | |
| Janssen Biotech, INC. | $197.59 | 2020-2025 | Erleada |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.